BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1872 related articles for article (PubMed ID: 8621219)

  • 1. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
    Yannelli JR; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg SA
    Int J Cancer; 1996 Feb; 65(4):413-21. PubMed ID: 8621219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
    Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
    Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Koo AS; Tso CL; Shimabukuro T; Peyret C; deKernion JB; Belldegrun A
    J Immunother (1991); 1991 Oct; 10(5):347-54. PubMed ID: 1790142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M; Rosenberg SA
    Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy.
    Chin Y; Janssens J; Smeyers E; Bleus J; Zhang J; Raus J
    Anticancer Res; 1992; 12(3):733-6. PubMed ID: 1622131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
    Itzhaki O; Hovav E; Ziporen Y; Levy D; Kubi A; Zikich D; Hershkovitz L; Treves AJ; Shalmon B; Zippel D; Markel G; Shapira-Frommer R; Schachter J; Besser MJ
    J Immunother; 2011 Mar; 34(2):212-20. PubMed ID: 21304398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.